1 |
Tremblay AJ, Morrissette H, Gagne JM, Bergeron J, Gagne C, Couture P. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem. 2004. 37: 785-790.
DOI
ScienceOn
|
2 |
Wilson PW, Zech LA, Gregg RE, Schaefer EJ, Hoeg JM, Sprecher DL, Brewer HB Jr. Estimation of VLDL cholesterol in hyperlipidemia. Clin Chim Acta. 1985. 151: 285-291.
DOI
ScienceOn
|
3 |
Wilson PW, Zech LA, Gregg RE, Schaefer EJ, Hoeg JM, Sprecher DL, Brewer HB Jr. Estimation of formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification cholesterol from data on triglyceride concentration in plasma. Clin Chem. 1981. 27: 2008-2010.
|
4 |
Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah: ascreeninganalysis. Hypertension 1991. 17: 969-976.
DOI
|
5 |
Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006. 113: 1888-1904.
DOI
ScienceOn
|
6 |
Labeur C, De Bacques D, De Backer G, Vinke J, Muyldermans L, Vandekerckhove Y. Plasma lipoprotein (a) values and severity of coronary Artery Disease in a Large population of patients undergoing coronary angiography. Clin Chem. 1992. 38: 2261-2266.
|
7 |
Laaksonen DE, Niskanen L, Lakka HM, Lakka TA, Uusitupa M. Epidemiology and treatment of the metabolic syndrome. Ann Med. 2004. 36: 332-346.
DOI
ScienceOn
|
8 |
McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM. DNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987. 300: 132-137.
|
9 |
Naito HK, Wada M, Erhart A. Polyacrylamide gel disc electrophoresis as a screening procedure for serum lipoprotein abnormalities. Clin Chem. 1973. 19: 228-234.
|
10 |
Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003. 139: 761-776.
DOI
ScienceOn
|
11 |
Pyrorala KG, De Backer I, Graham P, Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European Societyof Cardiology, Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994. 110: 121-161.
DOI
ScienceOn
|
12 |
Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens. 1991. 9: 217-223.
DOI
ScienceOn
|
13 |
Scott MG, Diane B, Luther TC, Richard SC, Margo AD, Wm JH, Donald BH, Russell VL, Patrick M, James MM, Richard CP, Neil JS, Linda VH. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001. 285: 2486-2497.
DOI
ScienceOn
|
14 |
Sesso HD, Buring JE, Chown MJ, Ridker PM, Gaziano JM. A prospective study of plasma lipid levels and hypertension in women. Arch Intern Med. 2005. 165: 2420-2427.
DOI
ScienceOn
|
15 |
Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: the San Antonio Heart Study. Arch Intern Med.1996. 156: 1994-2000.
DOI
ScienceOn
|
16 |
Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998. 81: 7B-12B.
DOI
ScienceOn
|
17 |
Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA. 2003. 289: 2560-2572.
DOI
ScienceOn
|
18 |
Cornoni HJ, LaCroix AZ, Havlik RJ. Race and sex differentials in the impact of hypertension in the United States. The National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med. 1989. 149: 780-788.
DOI
ScienceOn
|
19 |
Dahlen GH, Stenlund H. Lp (a) lipoprotein is a major risk factor for cardiovascular disease. Pathogenic mechanisms and clinical significance. Clin Genet. 1997. 52: 272-280.
|
20 |
Falco C, Estelles A, Dalmau J, Espana F, Aznar J. Influence of lipoprotein (a) levels and isoforms on fibrinolylic activity, study in families with high lipoprotein(a) Levels. Thromb-Haemost. 1998. 79: 818-823.
|
21 |
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972. 18: 499-502.
|
22 |
Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002. 106: 2137-2142.
DOI
ScienceOn
|
23 |
Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension. The San Antonio Heart Study. Arch Intern Med. 1996. 156: 1994-2001.
DOI
ScienceOn
|
24 |
Gotto J, Antonio M. Evolving concepts of dyslipidemia, atherosclerosis, and cardiovascular disease. J Am Coll Cardiol. 2005. 46: 1219-1224.
DOI
ScienceOn
|
25 |
Groop L, Orho MM. The dysmetabolic syndrome. J Intern Med. 2001. 250: 105-120.
DOI
ScienceOn
|
26 |
Haffner SM, Ferrannini E, Hazuda HP, Stern MP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992. 20: 38-45.
DOI
|
27 |
Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in arteriosclerosis. Nature 1989. 39: 303-315.
|
28 |
Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Michael Gaziano J. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006. 47: 45-50.
DOI
|